Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis

Indian Journal of Medical Research

Volumn 134, Issue 11, 2011, Pages 696-703

  Faujdar, Jaya ^a   Gupta, Pushpa ^a   Natrajan, Mohan ^a   Das, Ram ^a   Chauhan, D S ^a   Katoch, V M ^a,b   Gupta, U D ^a  

^a NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Chemotherapy; Immunotherapy; Mycobacterium tuberculosis; Mycobacterium w

Indexed keywords

AMIKACIN; BCG VACCINE; CYCLOSPORIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MOXIFLOXACIN; MYCOBACTERIUM W VACCINE; PARA AMINO SALISALIC ACID; PYRAZINAMIDE; RIFAMPICIN; SALICYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIUM ISOLATE; BCG VACCINATION; COLONY FORMING UNIT; CONTROLLED STUDY; GENE AMPLIFICATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCOBACTERIOSIS; NONHUMAN;

EID: 82155164384     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.90999     Document Type: Article

References (28)

1. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 2009; 87: 683-91.
2. Nunes EA, De Capitani EM, Coelho E, Joaquim OA, Figueiredo IRO, Cossa AM, et al. Patterns of anti-tuberculosis drug resistanceamong HIV infected patients in Maputo, Mozambique, 2002-2003. Int J Tuberc Lung Dis 2005; 9: 494-500.
3. WHO. Global tuberculosis control. Geneva: WHO; 2010.
4. RNTCP Report: TB India 2011. Available from: http://www. tbcindia.org, accessed on August 20, 2011.
5. Fine PEM. Variation in protection by BCG: implication of and for heterologous immunity. Lancet 1995; 346: 1339-45.
6. Ly LH, McMurray DN. Tuberculosis: Vaccine in pipeline. Expert Rev Vaccines 2008; 7: 635-50.
7. Gupta UD, Katoch VM, Mcmurray DN. Current status of TB vaccines. Vaccine 2007; 25: 3742-51.
8. Katoch VM. Vaccines for Mycobacterial diseases: A review. Punjab Univ Res Bull 2000; 52: 1-12.
9. Ahmed S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 2007; 87: 123-9.
10. Singh IG, Mukherjee R, Talwar GP. Resistance to inoculation of Mycobacetrium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobaceterium w. Vaccine 1991; 9: 10-4.
11. Talwar GP, Zaheer SA, Mukherjee R, Walia R, Misra R, Sharma AK, et al. Immuotherapeutic effects of vaccine based on a saprophytic cultivable Mycobacterium w, in multi-bacillary leprosy patients. Vaccine 1990; 8: 121-9.
12. Katoch K, Katoch VM, Natrajan M, Sreevatsa, Gupta U.D., Sharma VD, et al. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy. Vaccine 2004; 22: 3649-57.
13. Talwar GP. Continuing challenges in tuberculosis research. Indian J Tuberc 1992; 39: 67-9.
14. Patel N, Deshpande MM, Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 2002; 100: 191-3.
15. Kim BJ, Lee KH, Park BN, Kim SJ, Bai GH, Kim SJ, et al. Differentiation of mycobacterium species by PCR-restriction analysis of DNA (342 base pairs) of the RNA polymerase gene (rpoB). J Clin Microbiol 2001; 39: 2102-9.
16. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of Mycobacteria to the species level by PCR and restriction enzyme analysis. J Clin Microbiol 1993; 31: 175-8.
17. Katoch VM, Parashar D, Chauhan DS, Singh DS, Sharma VD, Ghosh S. Rapid identification of mycobacterium by gene amplification restriction analysis technique targeting 16S-23S ribosomal DNA spacer and flanking regions. Indian J Med Res 2007; 125: 155-62.
18. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin micro titer assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2720-2.
19. Martin A, Camacho M, Portaels F, Palomino JC. Resazurin micro titer assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003; 47: 3616-9.
20. Jain R, Dey B, Dhar N, Rao V, Singh R, Gupta UD, et al. Modulation of cytokine milieu in lungs by recombinant BCG over expressing Ag85C confers enhanced and long lasting protection against tuberculosis. PLoS Pathogen 2008; 3: 1-11.
21. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496-514.
22. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49: 2816-21.
23. Lenaerts AM, Chase SE, Chmielewski AJ, Cynamon MH. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 1999; 43: 2356-60.
24. Klemens SP, Destefano MS, Cynamon MH. Therapy of mutidrug-resistant lesions from studies with mice. Antimicrob Agents Chemother 1993; 37: 2344-7.
25. Gupta A, Geetha N, Mani J, Upadhyay P, Katoch VM, Natarajan M, et al. Immunogenicity and protective effcacy of Mycobacterium w against M. tuberculosis in mice immunized with live versus heat killed M. w by the aerosol or parenteral route. Infect Immun 2009; 77: 223-31.
26. Lounis N, Veziris N, Chauffour A, Pernot CT, Andries K, Jarlier V. Combination of R207010 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006; 50: 3543-7.
27. Wada M. The adverse reaction of anti-tuberculosis drugs and its management. Nippon Rinsho 1998; 56: 3091-5.
28. Siddiqi N, Shamim M, Hussain S, Choudhary RK, Ahmed N, Prachee, et al. Molecular characterization of multidrug-resistant isolates of tuberculosis from patients in north India. Antimicrob Agents Chemother 2002; 46: 443-50.